Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA's Medical Countermeasure Program Among Senate Funding Priorities

Executive Summary

FDA should spend $19 million of an increase in non-user fee funding in fiscal 2012 on the agency’s medical countermeasures effort, the Senate Appropriations Committee recommends in the report that accompanies the Agriculture/FDA appropriations bill approved by the panel Sept 8.

You may also be interested in...

FDA’s Generic Drug Office Goes On Diet Before Swallowing User Fees

Congress sets $52.9 million floor for Office of Generic Drugs in FY 2012, less than in 2011, as part of $3.8 billion FDA funding package. Overall, FDA gets a $50 million boost, but sequestration looms. Appropriations conferees enter the user fee debate, asking how fast FDA approves drug applications.

Obama's Drug Shortage Efforts Focus On Personnel, Persuasion

Executive order gives FDA no new authority, but will allow doubling of shortage staff and likely bolster issue awareness.

ANDA User Fee Negotiations Finished; Backlog To Be Mostly Cleared By Year Five

The finalized generic drug user fee agreement would clear most of the ANDA application backlog by the end of the first program cycle.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts